In the SURMOUNT trials evaluating tirzepatide for weight management, diarrhea rates were somewhat higher, affecting approximately 18-23% of participants
Notably, some users report a reduction in cravings for not just food but also substances like alcohol and nicotine, suggesting a potential role in managing addictive behaviors
Either way, they end up taking them indefinitely while exposing themselves to unneeded risks
Develop Clinical Protocols Intake questionnaire : BMI calculation, medical history, prior weight loss attempts, psychiatric screening Initial visit template : Comprehensive history, discussion of risks/benefits, informed consent, treatment plan with lifestyle modifications Follow-up template : Weight, vital signs, side effects, med tolerance, labs as needed Documentation : Justify BMI criteria, note nutritional counseling provided, record PMP checks for controlled substances 4
Patients were randomly assigned to receive semaglutide 1.0 mg or placebo once weekly